Alzheimer Disease
Conditions
Brief summary
Herein, investigated the effects of 4 weeks of H2 gas inhalation on community-dwelling adults of various ages.
Detailed description
Molecular hydrogen (H2) is a versatile therapeutic agent. H2 gas inhalation is reportedly safe and has a positive impact on a range of illnesses, including Alzheimer's disease (AD). Herein, investigated the effects of 4 weeks of H2 gas inhalation on community-dwelling adults of various ages. Fifty-four participants including those dropped out (5%) were screened and enrolled. The selected participants were treated as a single group without randomization. Evaluated the association between total and differential white blood cell (WBC) counts and AD risk at individual levels after 4 weeks of H2 gas inhalation treatment. Furthermore, evaluation of dementia-related biomarkers such as beta-site APP cleaving enzyme 1 (BACE-1), amyloid beta (Aβ), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor A (VEGF-A), T-tau, monocyte chemotactic protein-1 (MCP-1), and inflammatory cytokines (interleukin-6).
Interventions
OTHERH2 gas inhalation
H2 gas inhalation treatment for 4 weeks in on community dwelling adults of various ages
Sponsors
Wonju Severance Christian Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Masking description
Before and after of treatment in single group
Intervention model description
Single Group Assignment
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
Inclusion * Age ranges 40-70 years * Healthy participants * Patients who are willing or able to follow the doctor's instructions * Fully understand the purpose and procedure of this clinical trial
Exclusion criteria
* Participants excluded those who have any disease * Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of white blood cell and its differential counts such as neutrophils (%), basophils (%) | 4 weeks | 4 weeks treatment of H2 gas inhalation in community dwelling adults of various ages |
| Measurement of oxidative stress markers such as reactive oxygen species (µM), and nitric oxide (µM) | 4 weeks | 4 weeks treatment of H2 gas inhalation in community dwelling adults of various ages |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of dementia biomarkers such as brain-derived neurotrophic factor (BDNF ng/mL) | 4 weeks | 4 weeks treatment of H2 gas treatment |
| Measurement of dementia biomarkers such as brain-derived neurotrophic factor amyloid beta (Aβ (pg/mL)) | 4 weeks | 4 weeks treatment of H2 gas treatment |
| Measurement of inflammatory markers such as interleukin 6 (pg/mL) | 4 weeks | 4 weeks treatment of H2 gas treatment |
Countries
South Korea
Outcome results
None listed